Navigation Links
Pebbles Along the 'Path' to Personalized Medicine

Panel discussion with Georgetown experts to address biotechnology, science, policy and ethical issues

WASHINGTON, June 22 /PRNewswire-USNewswire/ -- Earlier this week, the National Institutes of Health and the Food and Drug Administration outlined a "path" to accelerate and help ensure the safety of personalized medicine -- treatments tailored to match a person's genetic make-up.  Significant progress in this rapidly developing field will hinge on biotechnology and will be impacted by the law, healthcare policy and ethical issues.

On Wednesday, June 23rd, Georgetown University Medical Center will explore the many issues of personalized medicine with a special panel featuring experts from healthcare, bioethics, policy and law.

Panelists for the event include:

  • Howard J. Federoff, MD, PhD, executive vice president for health sciences; executive dean of Georgetown University School of Medicine
  • Kevin T. Fitzgerald, SJ, PhD, research associate professor in the Department of Oncology; Dr. David P. Lauler Chair in Catholic Health Care Ethics
  • Lawrence O. Gostin, faculty director of the O'Neill Institute for National and Global Health Law; Linda D. and Timothy J. O'Neill Professor of Global Health Law
  • Patrick Maguire, MD, PhD, president and CEO of Cyberheart, Inc.
  • Stephen R. Seiler, founder and CEO of AesRx LLC

*The event will be moderated by Maggie Little, PhD,  associate professor in the Department of Philosophy; director and senior research scholar at the Kennedy Institute of Ethics

Background of scientific experts:

Howard J. Federoff

Kevin T. Fitzgerald

Lawrence O. Gostin

Patrick Maguire

Stephen R. Seiler

Maggie Little

The presentation will take place at the Bethesda North Marriott Hotel & Conference Center (5701 Marinelli Road, Bethesda, MD, 20852) at 7:00 PM ET on June 23rd, 2010. Media interested in attending, please contact Tressa Iris Kirby, GUMC Communications Officer, by calling 202-687-8865 or emailing A podcast of the discussion can be made available by request (24 hours prior to the event).

About Georgetown University Medical Center
Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health). GUMC's mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis -- or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing and Health Studies, both nationally ranked, the world-renowned Lombardi Comprehensive Cancer Center and the Biomedical Graduate Research Organization (BGRO), home to 60 percent of the university's sponsored research funding.

SOURCE Georgetown University Medical Center
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
2. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
3. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
4. Discussions With FDA on Pixantrone EXTEND (PIX301) Trial Provide Path for NDA Submission
5. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
6. Reminder: XTL to Hold a Conference Call Today at 8:30 am EDT to Discuss the Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
7. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
8. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
9. PATH, World Health Organization, and Partners Introduce Meningitis Vaccine in Burkina Faso
10. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
11. Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics Tissue of Origin Test Designed to Aid in Determination of a Tumors Origin
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS announces ... addition of its newest module, US Hemostats & Sealants. , SmartTRAK’s US Market ... hemostats, fibrin sealants, synthetic sealants and biologic sealants used in surgical applications. BioMedGPS ...
(Date:10/12/2017)... (PRWEB) , ... October 12, ... ... ) has launched Rosalind™, the first-ever genomics analysis platform specifically designed for ... complexity. Named in honor of pioneering researcher Rosalind Franklin, who made a ...
(Date:10/11/2017)... ... October 11, 2017 , ... The ... endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. ... is transformative for performing systematic gain-of-function studies. , This complement to loss-of-function ...
(Date:10/11/2017)... USA (PRWEB) , ... October 11, 2017 , ... ComplianceOnline’s ... take place on 7th and 8th June 2018 in San Francisco, CA. The Summit ... as well as several distinguished CEOs, board directors and government officials from around the ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
Breaking Biology News(10 mins):